Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Docetaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + cisplatin is a combination chemotherapy regimen used primarily for the treatment of non-small cell lung cancer (NSCLC), as well as other cancers such as prostate, head and neck, and gastric cancers. Docetaxel is a taxane antineoplastic agent that binds to microtubules, stabilizing them and preventing their depolymerization, which inhibits mitotic cell division and induces apoptosis in cancer cells[6][8]. Cisplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to DNA damage and apoptosis. The combination exploits complementary mechanisms—docetaxel disrupts microtubule function while cisplatin damages DNA—to enhance cytotoxicity against tumor cells[5][8]. This regimen is approved for first-line therapy in advanced or metastatic NSCLC and has demonstrated efficacy in adjuvant/neoadjuvant settings[1][2][5].
- Brand names
- Taxotere
- Other names
- DC regimenCISPDOCE
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Docetaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Docetaxel + cisplatin.